Summary

Original source:
http://today.reuters.com/business/newsArticle.aspx?type=health&storyID=nT209286

Details

• Japan's Takeda Pharmaceutical Co. (4502.T: Quote, Profile, Research) said on Friday its experimental diabetes drug SYR-322 has entered phase III clinical studies in the United States while its obesity medicine ATL-962 has begun phase II studies in Japan.
• Japan's biggest drug maker has been stepping up development of new drugs to help mitigate the impact of the expiry of U.S. patents on its main products -- ulcer drug Prevacid in 2009, and Blopress hypertension treatment and diabetes medicine Actos in 2011.
• Takeda said the SYR-322 is a DPP4 inhibitor, a drug which blocks the degradation of a kind of peptide that helps increase the secretion of insulin and helps to maintain the concentration of the peptide in blood for a longer period of time.
• The Osaka-based company did not say how much in sales it expected from the new drug, but it has high expectations for SYR-322.
• Takeda is also developing another diabetes drug which is expected to succeed Actos.
• As a result of the advancement in clinical development of SYR-322, Takeda will give a $15 million milestone payment to U.S. bioventure Pharmaceutical Product Development Inc., which used to develop the drug with Takeda's U.S. unit.
• Takeda will also pay $2 million to U.K. bioventure Alizyme Plc (AZM.L: Quote, Profile, Research) since ATL-962 has moved to the phase II stage, the spokesman said.
• Takeda acquired the right to develop, produce and sell ATL-962 in Japan in 2004 and has paid $5 million so far to Alizyme.
• Shares in Takeda closed up 0.47 percent at 6,350 yen prior to the announcement.

Related Articles

Popular Topics: Diabetes, Japan, Medicine, Diabetes, Breast cancer, Prostate cancer, Heart disease, Depression, High cholesterol, Osteoporosis, Vaccines, Autism, ADHD, Infertility, Weight loss, Cancer, Alzheimer's, Trans fats, Acrylamides, Fluoride, Mercury	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/018729_diabetes_Japan_medicine.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. <a href = "http://www.NaturalNews.com/018729_diabetes_Japan_medicine.html">Japanese diabetes drug progresses to third phase of clinical testing</a>
Receive our Natural Health Newsletter for FREE Subscribe now (it's free!) to win. We randomly choose a subscriber each month to send $100 in eco-home products or a RealGoods.com gift certificate (our choice). Plus, you'll receive FREE news, articles and action alerts from NaturalNews.com editors and join over 800,000 monthly readers who report extraordinary health improvements after becoming a subscriber! Receive breaking news alerts on natural health solutions, renewable energy, the environment, global warming and more. Receive a free instant download of our $29 Secret Sources guide that reveals top sources for little-known health and diet solutions.	Your Email Address: Free Subscription Code: Enter the numbers you see: 100% free of charge. Unsubscribe anytime. Absolutely no spam. We respect your email privacy.
Recommended Special Report: Seven Words that can Change the World by Joseph R. Simonetta Read this special report now... "Seven Words That Can Change the World reveals the astonishing, simple truths that have the power to forever transform our world for the better while freeing our minds from the enslavement of limiting beliefs. This is not a text for the simple-minded; it is a guiding philosophy for the mindful, intelligent few who are wise enough to seek out -- and recognize -- the higher simplicities of truly purposeful living." - Mike Adams, the Health Ranger, editor of NaturalNews.com	More on NaturalNews.com: • Streaming Health Ranger Videos • CounterThink Cartoons • FREE Special Reports • Podcasts